To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/9872/Sevindik-Omur-2022.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2022Author
Sevindik, Ömür GökmenMergen, Mahmut
Mergen, Sena
Mutlu, Yaşa Gül
Balık Aydın, Berrin
Serin, İstemi
Metadata
Show full item recordCitation
Sevindik, Ö. G., Mergen, M., Mergen, S., Mutlu, Y. G., Balık Aydın, B. ve Serin, İ. (2022). To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission. Annals of Hematology, 101(11), 2545-2547. https://doi.org/10.1007/s00277-022-04938-0Abstract
Dear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. Allogeneic stem cell transplantation has signifcantly prolonged the overall survival in a particular “eligible” patient population, but as AML is a disorder of the elderly, not all patients are able to proceed with allogeneic stem cell transplantation.